Cells were treated with various concentrations of URB597 or 4-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide (BCTC) (0.02, 0.5, 2 mol/L, Cayman Chemical Company, Ann Arbor, MI, USA), SR144528 (0.02, 0.5, 2 mol/L, EMD Millipore, Etobicoke, ON, Canada), indomethacin (2, 20, 50 mol/L, Sigma-Aldrich, Oakville, ON, Canada), or vehicle solution (0.1% dimethyl sulfoxide, DMSO) and incubated for 15 min at 37 C in 5% CO 2
Disturbances in the secretion of these hormones or the activity of EECs can impair these processes, contributing to metabolic diseases such as obesity and type 2 diabetes
Qian XP, Zhang XH, Sun LN, Xing WF, Wang Y, Sun SY, et al
Dementia Trialists Collaboration JAMA 1998
GLP-1 Medications & Your Gut: What We Know (and Dont) So Far GLP-1s (and their cousins like the dual GLP-1/GIP agonist tirzepatide) are powerful tools for type 2 diabetes and medical weight management